Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.37 and traded as low as $2.17. Oramed Pharmaceuticals shares last traded at $2.17, with a volume of 116,824 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday.

Oramed Pharmaceuticals Stock Performance

The company has a market capitalization of $87.48 million, a price-to-earnings ratio of 19.73 and a beta of 1.66. The company has a 50-day moving average price of $2.36 and a 200-day moving average price of $2.37.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. BML Capital Management LLC boosted its position in shares of Oramed Pharmaceuticals by 20.9% during the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company’s stock worth $6,398,000 after purchasing an additional 457,716 shares in the last quarter. World Equity Group Inc. bought a new position in Oramed Pharmaceuticals during the fourth quarter worth about $48,000. Peapod Lane Capital LLC acquired a new position in Oramed Pharmaceuticals in the fourth quarter valued at about $550,000. Marquette Asset Management LLC bought a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth about $81,000. Finally, XTX Topco Ltd raised its position in shares of Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 9,242 shares during the period. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.